Research on Integrity in Collaborative Research (R21)
The summary for the Research on Integrity in Collaborative Research (R21) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Research on Integrity in Collaborative Research (R21): Purpose. This FOA issued by NCRR, FIC, NIBIB ORI and OHRP encourages research grant applications from institutions/organizations that propose to study research integrity as it relates to collaborative interactions and/or activities. The R21 exploratory/developmental mechanism will be used to foster research where there are few published data and where problem areas that would benefit from further investigation could be identified. Applications must address the influence of collaborative interactions and/or activities on research integrity in at least one of the following areas that are of particular interest to the ORI and NIH: the clarification of community norms and standards, the effectiveness of self-regulation, the societal, organizational, group, or individual factors that affect integrity in research, both positively and negatively, or the impacts of non-adherence to accepted codes of conduct. The proposed project must challenge existing paradigms, be developed around an innovative hypothesis or address critical barriers to progress in understanding the multiple factors that underlie deviation from integrity in collaborative research. Proposals must have clear relevance to biomedical, behavioral health sciences, or health services research. Applicants are encouraged to take into consideration problems or issues that have relevance to the specific interests of ORI or NIH Institutes and Centers. Mechanism of Support. This FOA will utilize the R21 grant mechanism. Funds Available and Anticipated Number of Awards. Funding for FY2010 is anticipated to be $850,000 in total costs to support two to three new R21 awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.
|Federal Grant Title:||Research on Integrity in Collaborative Research (R21)|
|Federal Agency Name:||National Institutes of Health|
|Grant Categories:||Education Health|
|Type of Opportunity:||Discretionary|
|Funding Opportunity Number:||RFA-RR-10-001|
|Type of Funding:||Grant|
|CFDA Descriptions:||Discovery and Applied Research for Technological Innovations to Improve Human Health|
|Current Application Deadline:||Apr 07, 2010|
|Original Application Deadline:||Apr 07, 2010|
|Posted Date:||Dec 01, 2009|
|Creation Date:||Dec 01, 2009|
|Archive Date:||May 08, 2010|
|Total Program Funding:||$850,000|
|Maximum Federal Grant Award:||$200,000|
|Minimum Federal Grant Award:|
|Expected Number of Awards:|
|Cost Sharing or Matching:||No|
- Applicants Eligible for this Grant
- State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
- Link to Full Grant Announcement
- Information not provided
- Grant Announcement Contact
- NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
- Similar Government Grants
- • Enhancing Science, Technology, EnginEering, and Math Educational Diversity (ESTEEMED) Rese...
- • National Centers for Biomedical Imaging and Bioengineering (NCBIB) (P41 Clinical Trials Op...
- • NIBIB Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional...
- • Perception and Cognition Research to Inform Cancer Image Interpretation (R01 Clinical Tria...
- • Team-Based Design in Biomedical Engineering Education (R25 Clinical Trial Not Allowed)
- • Exploratory Grants (P20) for NIBIB Quantum Projects
- • Nibib Research Supplements to Promote Clinical Resident Research Experiences
- • Innovation in Molecular Imaging Probes
- More Grants from the National Institutes of Health
- • Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Administrative Resource...
- • Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Research Resource (U24)...
- • New Cohorts for Environmental Exposures and Cancer Risk (CEECR; UG3/UH3 Clinical Trial Not...
- • Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical ...
- • Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Tria...